No FDA psychedelic approval or advisory committee action occurs before Q4 2026.

Before the FDA approves any drug, it usually holds a public advisory committee meeting — basically a panel of outside experts who debate whether the evidence is strong enough. Right now, no such meeting is scheduled for any psychedelic drug, and the FDA's calendar is empty on this front. The most recent attempt, MDMA for PTSD, was rejected partly because of problems with how the clinical trials were run. Until those problems are solved, nothing moves forward. This matters because FDA approval is the gateway to legal prescriptions, insurance coverage, and wider access.

Empty docket plus FDA evidentiary standards. Confirmatory data and functional unblinding concerns from the MDMA file remain unresolved, and no advisory committee meeting is currently scheduled. This is sharply falsifiable: any FDA approval or AdComm convening on a psychedelic before Oct 1, 2026 resolves it false.